Johnson & Johnson JNJ

$280.78 -1.33 (-0.47%)

Valuation

Market cap
664,947,200,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
P/E (trailing)
25.57
P/E (forward)
24.50
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
7,383,700
Avg volume
7,236,090
Day's range
$279.19 – $283.25
Shares out
2,407,310,000
Stochastic %K
97%
Beta
0.22
Analysts
Moderate Buy
Price target
$281.64

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

Biotechsamy Nov 10, 10:36 PM
$LEGN if In Vivo CAR-T clinical data was not promising, Frank at LEGN would have sold the company to $JNJ earlier this year at the best price possible that he could negotiate, before it’s get ugly with Anito cel approval. But he didn’t budge probably for a reason. Let’s hope for the best outcome, but not everyone can practice patience.
0 replies
JFais Nov 10, 10:21 PM
Key ?'s for $JNJ's bleximenib ASH abstract: -1/3rd of patients missing from their efficacy analysis (ITT 146, 100 EEP) Were there deaths or patients coming off drug early? Grade 3+ cytopenias 35%, also seeing DS, QTc & myelosuppression (could have problems with combinations) (more notes on the menin space in Chat)
0 replies
Gebinator Nov 10, 8:47 PM
$SLS @OnTheBalance the MEGA FLOSS 4: $JNJ $MRK $ABBV $LLY $40 Billy 🦖 MINIMUM
0 replies
GettnFibbywIT Nov 10, 8:34 PM
$JNJ $XLV $IHE JNJ - Weekly Chart (*Final weekly print TBD) JNJ has clearly accepted the $263 level and is increasingly establishing a higher support shelf in the $266 - $264 ish area. The pattern of rising lows, bullish momentum confirmation, and multiple weekly closes above former resistance suggests buyers remain in control - (Unless price begins losing acceptance beneath the lower support band). *$275 -Recent Resistance / Prior High *$270 -Secondary Support *$264 - $266 -Behavioral Support (recent lows/opens/closes) *$263 -Major Structural Breakout Level For those who employ structured credit spread trading strategies, short strikes below the identified areas of defined structural risk appear to be attractive (not a recommendation to buy/sell ). Good luck out there sports fans..........
0 replies
ScienceBling Nov 10, 7:22 PM
$SLS $LLY & $JNJ are BEHEMOTHS able to BUYOUT $£$ 250! Table shows ££Y with FDA approved Abemaciclib (CDK 4/6 inhibitor) in breast CA & multiple BLOOD cancer expertise (e.g., MDS, MF, DLBLC, Myeloma) & JNJ with AML/DLBCL expertise & multiple solid tumors assets. BOTH ££Y & JNY will benefit tremendously from owning the entire AML francise in addition to SOLID tumors expansion, especially in drug-resistant TP53 and ASXL1 mutated tumors and WT1+ platform for curative-intent maintenance FOREVER REVENUE! $£$ BUYOUT WILL LIKELY settle near $£$ BLUESKY valuation while BIG PHARMA gets their FINAL REVENUES worth 100's of BILLIONS from using their resources to fully develop GPS WT1+ and SLS009 CDK9 inhibitor PLATFORMS ! NOW YOU KNOW WHY THERE IS SO MUCH $£$ PRICE MANIPULATION UNTIL BUYOUT! $£$ 250!
0 replies
theoptionsplug Nov 10, 7:02 PM
$JNJ has once again struggled and rejected the $280 resistance area A break of $278.75 is the put trigger targeting $275.25 then $271.35
0 replies
BurchJJ Nov 10, 6:57 PM
$CNSY so it begins $RKLB $JNJ $SPY
0 replies
TraderDaKing Nov 10, 6:12 PM
$ELTP $GME $JNJ $PFE In late 2025, Elite Pharmaceuticals’ management explicitly stated that pursuing mergers and acquisitions (M&A) was a preferred strategic path. The company set a soft deadline through the end of 2025 into early 2026 to see if an attractive M&A or buyout deal materialized. If no suitable deal emerged, management planned to shift focus toward uplisting the stock from the OTC market to the NASDAQ exchange. • Asset Appeal: Elite holds strong market positions in key generic lines, particularly central nervous system (CNS) medications like ADHD drugs • Infrastructure: Its physical facility space is set up to handle controlled substances, which is an attractive operational footprint for larger pharmaceutical buyers. • Elite added new board members, including John W. LaRocca, Esq., and Aqeel A. Fatmi, Ph.D.. Retail investors have speculated that bringing on individuals with legal, regulatory, and pharma integration experience could be a sign.
0 replies